Table 3 Multivariate Cox regression analysis for PFS in all subjects.

From: Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis

Variable

 

Unsupervised cluster

Supervised cluster

MTV

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Age

 < 58

         

58 ~ 67

0.97

0.59–1.59

0.897

0.92

0.55–1.51

0.730

0.97

0.87–1.61

0.916

67 ≤ 

0.84

0.43–1.61

0.591

0.78

0.41–1.51

0.468

0.81

0.42–1.59

0.540

ASCT

No

         

Yes

0.37

0.21–0.63

 < 0.001

0.33

0.19–0.57

 < 0.001

0.38

0.22–0.66

 < 0.001

R-ISS stage

I

         

II

0.89

0.53–1.50

0.663

0.84

0.50–1.43

0.523

0.85

0.50–1.45

0.549

III

1.28

0.68–2.42

0.444

1.17

0.61–2.26

0.632

1.42

0.75–2.71

0.286

Anemia

No

         

Yes

1.40

0.92–2.12

0.117

1.33

0.86–2.04

0.196

1.30

0.85–2.00

0.230

Unsupervised cluster

A

         

B

1.05

0.69–1.61

0.822

      

C

2.68

1.50–4.79

 < 0.001

      

Supervised cluster

A

         

B

   

0.98

0.63–1.54

0.940

   

C

   

2.42

1.37–4.29

0.002

   

MTV

Low

         

Moderate

      

0.80

0.46–1.38

0.419

High

      

2.01

1.28–3.16

0.002

  1. ASCT autologous stem cell transplantation, PFS progression-free survival, R-ISS revised multiple myeloma international staging system, MTV metabolic tumor volume.
Back to article page